Clinical Trial

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-25; most recent amendment 2026-05-19.
Trial Details
NCT Number NCT07150091
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 20 participants
Start Date 2022-07-19
Primary Completion 2025-04-17 (estimated)
Study Completion 2027-03-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-16